ACTU
14/05/2026Résumé IA
Eli Lilly Focuses on Alzheimer's Innovation, Launches Lormalzi in India
Eli Lilly prioritizes Alzheimer's in its innovation pipeline, launching Lormalzi (donanemab), a monthly amyloid-targeting therapy for early Alzheimer's, priced at ₹91,688 per vial in India.
E
Economic Times1 min de lecture